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Non-Hodgkin lymphomas encompass a heterogeneous group of cancers, with 85–90% arising from B lymphocytes and the
remainder deriving from T lymphocytes or NK lymphocytes. These tumors are molecularly and clinically heterogeneous, showing
dramatically different responses and outcomes with standard therapies. Deregulated PI3K signaling is linked to oncogenesis
and disease progression in hematologic malignancies and in a variety of solid tumors and apparently enhances resistance to
antineoplastic therapy, resulting in a poor prognosis. Here, we have evaluated and compared the effects of the pan-PI3K inhibitor
BKM120 and the dual PI3K/mTOR inhibitor BEZ235 onmantle, follicular, and T-cell lymphomas. Our results suggest that BKM120
and BEZ235 can effectively inhibit lymphoma cell proliferation by causing cell cycle arrest and can lead to cell death by inducing
apoptosis and autophagy mediated by ROS accumulation. Despite great advances in lymphoma therapy after the introduction
of monoclonal antibodies, many patients still die from disease progression. Therefore, novel treatment approaches are needed.
BKM120 and BEZ235 alone and in combination are very effective against lymphoma cells in vitro. If further studies confirm their
effectiveness in animal models, they may be promising candidates for development as new drugs.
1. Introduction
The phosphatidylinositol 3-kinase [PI3K] signaling path-
way plays important roles in many physiological functions,
including cell cycle progression, differentiation, survival,
motility, apoptosis, autophagy, and protein synthesis [1–4].
PI3K activation leads to phosphorylation of AKT onThr308,
which in turn activates the mammalian target of rapamycin
(mTOR), a distal element of the PI3K/AKT/mTOR pathway
[5]. mTOR is a serine/threonine kinase that encompasses
two distinct complexes—mTORC1 andmTORC2—that differ
structurally and in substrate specificity and functionally [6].
mTORC1 induces cell growth in response to nutrients and
growth factors by regulating the translational regulators S6K1
and 4E-BP1. mTORC2 mediates cell proliferation and sur-
vival by phosphorylating AKT on Ser473, facilitating its full
activation [7–10]. The PI3K/Akt/mTOR pathway integrates
survival signals from extracellular and intracellular stimuli to
promote cell growth and inhibit cell death [11]. This pathway
is also involved in regulating autophagy, the ubiquitous and
evolutionarily conserved process through which cytosolic
components are degraded via lysosomes, helping cells to
survive various forms of stress [12]. There remains some
debate regarding the precise role that autophagy plays in
cancer development, disease progression, and response to
anticancer therapies [13]. In contrast to apoptosis, autophagy
is initially a survival mechanism triggered when cells are
exposed to metabolic stresses. However, recent studies indi-
cate that autophagy and apoptosis are actually interconnected
processes [14].
Deregulated PI3K signaling is linked to oncogenesis
and disease progression in a variety of solid tumors and
hematologic malignancies, apparently enhancing resistance
to antineoplastic therapy and resulting in poor prognosis
[15]. PI3K discovery and subsequent mapping of the signal-
ing pathway heralded intense efforts to develop inhibitors
targeting the pathway components [16–18]. A number of
PI3K/AKT/mTOR signaling inhibitors have been developed
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that selectively interfere with different pathway components
and thus exert different biological effects. However, the initial
enthusiasm for using PI3K, Akt, or mTOR inhibitors as
antineoplastic agents has been tempered by observations that
such inhibition typically promotes growth arrest rather than
cell death in solid tumors [19].
BKM120 and BEZ235 are synthetic small molecules of
the imidazoquinolines class, which show preclinical activity
against a range of solid and hematological malignancies.
BKM120 is an oral pan-class I PI3-kinase inhibitor belonging
to the 2,6-diporpholino pyrimidine derivatives. It selectively
inhibits PI3K 𝛼, 𝛽, 𝛾, and 𝛿, as well as mutated PI3K
(H1047R, E542K, and E545K). BKM120 reportedly inhibits
phosphorylation of the PI3K downstream target Akt and
exhibits antiproliferative activity in several cancer cell lines
[20–22]. BKM120 shows preclinical activity in distinct malig-
nancies and is currently being tested in a number of clinical
trials (ClinicalTrials.gov, U.S. National Institutes of Health,
Bethesda, MD, USA: http://clinicaltrials.gov/). BEZ235 is a
dual class I PI3K/mTOR inhibitor that competes at its ATP-
binding site [23–25]. Increasing evidence demonstrates that
BEZ235 effectively and specifically reverses hyperactivation
of the PI3K/mTOR pathway, thus exerting potent antiprolif-
erative and antitumor activities in a broad range of cancer
cell lines and experimental tumors. It is currently undergoing
phase I evaluation in acute leukemia [NCT01756118] [26, 27].
Promising preclinical and clinical data support the ratio-
nale for therapeutic use of PI3K/Akt/mTOR inhibitors in
lymphoma treatment [28] and, crucially, these inhibitors are
well tolerated. However, despite the progress in pharmaco-
logical targeting of PI3K signaling, several important issues
must be considered. The considerable plasticity within the
PI3K signaling pathwaymakes it unlikely that PI3K inhibitors
will provide a universal therapy across the range of diseases in
which PI3K has been implicated. Non-Hodgkin lymphomas
encompass a heterogeneous group of cancers, with 85–90%
arising from B lymphocytes and the remainder deriving
from T or NK lymphocytes. These tumors are molecularly
and clinically heterogeneous, showing dramatically different
responses and outcomes with standard therapies.
The present study aimed at investigating the effects
of BKM120 and BEZ235 on mantle, follicular, and T-cell
lymphoma cell lines and patients’ cells.We evaluated possible
new targets and potential strategies for enhancing the anti-
cancer efficacy of these two compounds.
2. Material and Methods
2.1. Cell Lines. The cutaneous T-cell lymphoma cell
line HUT78 and the mantle cell lymphoma cell line
GRANTA519 were purchased from Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH and were
characterized as specified (https://www.dsmz.de/research/
human-and-animal-cell-lines.html). The B-cell lymphoma
cell line WSU-NHL was kindly provided by Dr. M. Introna
(Ospedale Riuniti, Bergamo, Italia). All cell lines were
cultured in RPMI-1640 supplemented with 10% fetal bovine
serum (FBS), 2mM L-glutamine, and 100U/mL penicillin
and streptomycin (all purchased from Euroclone). Cells in
logarithmic growth phase were used for experiments.
2.2. Patient Samples. Peripheral blood mononuclear cells
(PBMCs) were obtained from three patients with mantle
cell lymphoma, four patients with follicular lymphoma, two
patients with T-cell lymphoma, and four authors of the paper
who volunteered. All donors gave their informed consent,
and this study protocol was approved by the local ethics
committee of University of Modena and Reggio Emilia.
2.3. Drugs. BKM120 was a gift from Novartis Pharma.
BEZ235 and everolimus were purchased from Selleck Chem-
icals. Chloroquine, paclitaxel, and nocodazole were pur-
chased from Sigma Aldrich (St. Louis, MO, USA). BKM120,
BEZ235, everolimus, and paclitaxel were each dissolved in
dimethylsulfoxide (DMSO; Euroclone) to create 10−2Mstock
solutions that were stored at −80∘C. The stock solutions
were further diluted with cell culture medium to appropriate
concentrations before use.Themaximum final concentration
of DMSO (<0.1%) did not affect cell proliferation and did not
induce cytotoxicity on the tested cell lines and primary cells
(data not shown).
2.4. Assessment of Viability and Cell Proliferation. Cell lines
were treated with increasing concentrations of drugs for
24 and 48 h. Viability was assessed by exclusion assay with
0.2% Trypan Blue (Euroclone), and cell proliferation was
monitored by MTT assay (CellTiter nonradioactive cell pro-
liferation assay; Promega) as previously described [29]. The
drug concentration required for 50% inhibition of cell prolif-
eration (IC
50
) was evaluated with Calcusyn software (Biosoft,
Cambridge, UK) applying the median-effect method [30].
2.5. Annexin IV Binding Assay for Apoptosis. Apoptosis was
quantified using an annexin/propidium iodide (PI) binding
assay following the manufacturer’s instructions (Miltenyi
Biotec). Eventswere acquired using a FACSCalibur cytometer
(BectonDickinson) and then analyzed using FlowJo Software
(Tree Star, Ashland, OR, USA).
2.6. Caspase-3 Activity Assay. Caspase-3 activity was mea-
sured using a colorimetric substrate for caspase-3 (CPP32)
(Enzo Life Sciences) with a sequence based on poly(ADP
ribose) polymerase (PARP) cleavage site Asp216 for caspase-
3. The full-length and the cleaved procaspase-3 were incu-
bated with the substrate for the indicated times, and the
cleavage rate was colorimetrically monitored at 405 nm.
2.7. Autophagy Detection. To measure autophagy in cell
lysates, we used the quantitative immunometric detection
method provided by the p62 (sequestosome 1) ELISA kit,
following the manufacturer’s instructions (Enzo Life Science,
Farmingdale, NY, USA).
2.8. Cell Cycle Analysis. Cell cycle analysis was performed
using propidium iodide (PI) staining (Miltenyi Biotec) and
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a FACSCalibur cytometer. The percentages of cells in the
subG1/G0 (dead cells), G1/G0, S, and G2/M phases were
calculated using Modfit LT software (Verity Software House,
Topsham, ME, USA).
2.9. Analysis of Tubulin Expression. Cells were seeded at
100,000 cells/well in 24-well plates in RPMI-1640 with
10% FBS, 100 𝜇g/mL penicillin, 100U/mL streptomycin, and
drugs at the indicated concentrations. After incubation for
different time durations, the cells were resuspended in
0.5mL microtubule-stabilizing buffer (80mM Pipes, 1mM
MgCl
2
, 5mM EDTA, and 0.5% Triton X-100) containing
0.5% glutaraldehyde at pH 6.8. After a 10min incubation at
room temperature, glutaraldehyde was quenched by addition
of 0.5mL of 0.25M glycine solution in PBS. Cells were
then spun at 1000 g for 7min, resuspended in 20𝜇L of
50𝜇g/mL RNase A in antibody diluting solution (Ab-Dil;
PBS, 0.2% Triton X-100, 2% bovine serum albumin, and 0.1%
NaN
3
; pH 7.4), and incubated overnight at 4∘C. The next
day, the cells were incubated with 𝛼-tubulin (1 : 50) in Ab-
Dil for 3 h at room temperature and then with anti-rabbit
IgG1-FITC. Finally, the cells were further diluted in 500 𝜇L
FACS buffer (PBS, 2% BSA, and 0.1% sodium azide; pH 7.2)
followed immediately by flow cytometry analysis. For each
sample, the mean fluorescence intensity was recorded using a
FACSCalibur cytometer and analyzed using FlowJo Software.
Tubulin levels were determined based on the geometricmean
of the antibody/FITC fluorescence and were normalized to a
value of 100 for the vehicle control. All of the abovementioned
reagents were purchased from Sigma Aldrich.
2.10. Western Blot Analysis. After drug treatments, the cell
lines were harvested and lysed using the Mammalian Cell
Extraction Kit (BioVision, Milpitas, CA, USA) following the
manufacturer’s instructions. Proteins (100 𝜇g/lane) were elec-
trophoresed on 4–20%SDS-polyacrylamide gradient gels and
transferred to nitrocellulose membranes (Bio-Rad Laborato-
ries, Hercules, CA, USA). Membranes were immunoblotted
with the following primary antibodies: total AKT, p-AKT (ser
473), total p70S6, p-p70S6 (Thr421/Ser424), total m-TOR, p-
m-TOR (ser 2448), total EBP1, p-EBP1 (Thr37/46), cyclin D,
cyclin E, cyclin A, p-21 (Waf1/Cip1), p-27 (Thr187), Aurora
A, p-BAD (Ser112), PUMA, BIM, MCL, BCL-XL, BCL-2,
caspase-3 (Asp175), caspase-9 (Asp353), caspase-8 (Asp391),
PARP, and LC3. All of the abovementioned antibodies were
diluted 1 : 1000 and purchased from Cell Signaling Technol-
ogy (Danvers, MA, USA). Then, the membranes were incu-
bated with species-specific horseradish peroxidase- (HRP-)
conjugated secondary antibody (1 : 500) from Cell Signal-
ing Technology. Blots were developed using SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientific,
Rockford, IL, USA). Images were acquired by Chemidoc
XRS+ and analyzed using Image Lab Software v.3.0 (Bio-Rad
Laboratories).
2.11. Measurement of Reactive Oxygen Species (ROS) Pro-
duction. To determine ROS production, cells were incu-
bated with 20𝜇M/L 2󸀠,7󸀠-dichlorodihydrofluorescein diac-
etate (DCFH-DA) (Sigma Aldrich) in complete medium for
30 minutes at 37∘C. The extent of ROS generation was mea-
sured by quantifying the fluorescence with a FACSCalibur
cytometer (Becton Dickinson), and these data were analyzed
using FlowJo Software (Tree Star).
2.12. Combination Study. Cell lines were seeded at 5 ×
104 cells per well in 96-well plates. Each experiment was
performed in triplicate. Cells were cultured in the absence
or presence of drugs, individually or in combination, at
concentrations below the IC
50
. The inhibitory effects of
drug combination treatments were determined using the
MTT assay as described above. Drug interactions were
assessed using multiple effect analysis, based on the method
described by Chou-Talalay in which a combination index
(CI) of <1 indicates synergism, 1 indicates additive effects,
and >1 indicates antagonism [31].The data were processed by
isobologram analysis using Stata 8.2.
2.13. Statistical Analysis. All experimentswere independently
repeated three times, with multiple replicates within each
run. Data are expressed as mean ± standard error. Statistical
differences between control and drug-treated cells were ana-
lyzed by one-way ANOVA and by two-tailed Student’s test.
Data were analyzed using the Stata 8.2/SE package (StataCorp
LP, College Station, TX, USA). Correlation coefficients (r)
and the statistical significance of differences between cohorts
were determined using Prism’s correlation analysis based on
two-tailed 𝑝 values (GraphPad Software, USA), with 𝑝 values
of <0.01 considered statistically significant.
3. Results
3.1. Growth Inhibition. To determine the IC
50
values and the
effects of the drugs on cell viability, lymphoma cell lines
were cultured with increasing concentrations of BKM120
(0.5–15𝜇M) and BEZ235 (0.5–50 nM) for 24 and 48 hours.
Table 1 shows the IC
50
values obtained for BKM120 and
BEZ235 in HUT78, GRANTA519, and WSU-NHL cell lines.
Results were obtained from three independent experiments
performed in triplicate. We also evaluated the drugs’ effects
on PBMCs from three patients with mantle cell lymphoma,
four patients with follicular lymphoma, two patients with
T-cell lymphoma, and four healthy donors (Figure 1). We
observed that BKM120 and BEZ235 each significantly and
dose-dependently decreased the percentage of viable PBMCs
from patients with lymphoma but had minimal or no cyto-
toxic effect on PBMCs from healthy donors. We treated the
cells for only 24 hours because 48 hours of treatment was too
toxic (data not shown).
3.2. Cell Cycle. We employed flow cytometric analysis to
determine whether 24 hours of treatment with the IC
50
of
BKM120 and BEZ235 led to cell cycle progression defects
(Figure 2). To investigate the effects of drugs on cell cycle-
related proteins, we used western blot analysis to evaluate
the expressions of cyclin A, cyclin D, cyclin E, p21, and
p27 (Figure 3). BKM120 induced a dose-dependent increase
of G2 phase with downregulation of cyclin D and cyclin E
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Figure 1: Antiproliferative effects of BKM120 and BEZ235 on
PBMCs from three patients with mantle cell lymphoma (MCL),
four patients with follicular cell lymphoma (FCL), two patients
with T-cell lymphoma (TCL), and four healthy donors. Cells were
treated with BKM120 (5𝜇M and 15𝜇M) and BEZ235 (20 nM and
40 nM) for 24 hours. Viability was assessed using 0.2% Trypan Blue
exclusion. Values represent mean ± SD and were obtained from
three independent experiments performed in triplicate. ∗𝑝 < 0.01
compared with control.
Table 1: Mean IC
50
values and 95% confidence intervals (CI) in
lymphoma cell lines treated with BKM120 (0.5–15 𝜇M) and BEZ235
(0.5–50 nM) for 24 and 48 hours. IC
50
values were calculated
using MTT assay and are based on three independent experiments
performed in triplicate.
(a)
BKM120 (𝜇M) IC
50
24 h IC
50
48 h
HUT78 15.1 4.8
(IC
95%: 14.8–15.4) (IC95%: 4.6–5.1)
GRANTA519 12.4 3.9
(IC
95%: 12.1–12.7) (IC95%: 3.4–4.2)
WSU-NHL 14.8 4.1
(IC
95%: 14.4–15.5) (IC95%: 3.8–4.6)
(b)
BEZ235 (nM) IC
50
24 h IC
50
48 h
HUT78 41.6 21.1
(IC
95%: 41.3–41.9) (IC95%: 20.9–22.4)
GRANTA519 45.1 25.3
(IC
95%: 44.8–46.2) (IC95%: 25.2–25.5)
WSU-NHL 39.2 18.5
(IC
95%: 39.01–39.5) (IC95%: 18.2–18.8)
and upregulation of cyclin A, p21, and p27. On the other
hand, BEZ235 induced an increase of G0/G1 phase, with
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Figure 2: Cell cycle profiles of HUT78, GRANTA519, and WSU-
NHL cells after 24 hours of treatment with the IC
50
of BKM120
and BEZ235. Data are expressed as mean ± SD, obtained from
three independent experiments performed in triplicate. ∗𝑝 < 0.01
compared with control.
downregulation of cyclin A and upregulation of cyclin D,
cyclin E, p21, and p27.
Immunoblotting revealed that all tested cell lines
expressed Aurora A kinase protein, which regulates cell-
cycle checkpoints and cell cycle regulatory molecules
(Figure 4) [32]. We next determined whether BKM120 and
BEZ235 inhibited Aurora A kinase expression in lymphoma
cell lines. To determine the compounds’ inhibitory effects
on the mitotic cell population, we first synchronized
cell division in lymphoma cell lines by treatment with
nocodazole (1 𝜇M) for 12 hours. The cells were then washed
and treated with BKM120 and BEZ235 for 24 h. Aurora A
kinase phosphorylation was measured by western blotting.
Decreased Aurora A kinase expression was observed in all
cell lines treated with BKM120, compared with in the DMSO
and nocodazole-treated cells.
3.3. Drug-Cell Correlations for Tubulin Assembly, Cycle Arrest,
and Cell Viability. Our findings indicated that BKM120
induced cell cycle arrest in G2, while BEZ235 induced arrest
in G1. By further analyzing intracellular tubulin polymer-
ization kinetics, cell cycle G2 population arrest, and cell
viability in dose response mode, we obtained a comprehen-
sive understanding of the drugs’ intracellular mechanisms
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Figure 3:Western blots of cellular extracts fromHUT78, GRANTA519, andWSU-NHL cell lines treatedwith the IC
50
of BKM120 andBEZ235
for 24 h. Cellular extracts were probed with antibodies against cyclin A, cyclin D, cyclin E, p21, and p27. Densitometric semiquantification of
bands normalized to the untreated control is shown below the immunoblot bands.
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Figure 4: Western blot of cellular extracts from HUT78, GRANTA
519, and WSU-NHL. The cells were treated (1) for 24 with 1𝜇M
nocodazole (NOCOD) and (2) for 24 with the IC
50
of BKM120
and BEZ235. Cellular extracts were probed with antibodies against
Aurora A. Densitometric semiquantification of bands normalized to
the untreated control is shown below the immunoblot bands.
of action at a molecular level. We utilized a cytometric-
based technique that allows direct quantitative evaluation
of tubulin/microtubule dynamics without interference from
microtubule-associated proteins or other complicating fac-
tors [33], thus enabling facile comparison of compounds that
affect tubulin polymerization.
HUT78, GRANTA519, and WSU-NHL were treated for
24 hours with increasing BKM120 concentrations along with
the microtubule destabilizer nocodazole (1𝜇M) and the
microtubule stabilizer paclitaxel (100 nM). This was followed
by whole cell-based qualitative measurement of tubulin poly-
merization using alpha-tubulin staining. Figure 5(a) shows
that BKM120 induced concentration-dependent progressive
induction of G2 arrest in HUT78 cells. Nocodazole and pacli-
taxel increased the G2 cell population arrest. In Figure 5(b),
the fluorescence reflecting cell tubulin assembly revealed
similar kinetics, as G2 cell population arrest was observed
after treatment with increasing concentrations of BKM120
and after treatment with the tubulin stabilizer paclitaxel.
Nocodazole had the opposite effect, as treatment with this
tubulin destabilizer clearly decreased tubulin polymerization.
Our results showed a positive correlation (𝑟 > 0.7) between
G2 cell population and tubulin assembly following treatment
with increasing doses of BKM120. Figure 5(c) shows a strong
negative correlation between tubulin assembly and cell via-
bility (𝑟 = −0.951). Comparable results were obtained with
GRANTA519 and WSU-NHL (data not shown).
HUT78 cells treated with increasing doses of BEZ235
showed a decrease in the G2 population, accompanied by a
parallel but very modest action on tubulin polymerization,
represented by a negative correlation index (𝑟 = −0.89)
(Figures 5(d) and 5(e)). Cell viability decreased in a dose-
dependent manner, which was not correlated with tubulin
assembly (𝑟 = −0.97) (Figure 5(f)). Comparable results
were obtained with GRANTA519 and WSU-NHL (data not
shown).
3.4. Signaling Pathways. To evaluate the effects of BKM120
and BEZ235 on PI3K/AKT/mTOR signaling, we analyzed the
phosphorylation status of Akt and some downstream targets
(including mTOR, 4EBP1, and p70S6kinase) in lymphoma
cell lines treated for 24 h with the IC
50
of these drugs. BEZ235
evidently reduced the expressions of PI3K/AKT/mTORpath-
way components in all cell lines (Figure 6). In the same
cellular lysates, we also evaluated the total expressions of the
corresponding proteins (data not shown).
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Figure 5: HUT78 cells were treated for 24 hours with increasing concentrations of BKM120 and BEZ235 as well as with the microtubule
destabilizer nocodazole (1 𝜇M) and the microtubule stabilizer paclitaxel (100 nM). Representative data from analyses of cell cycle arrest in
G2 (a), tubulin polymerization (b), and cell viability (c) after BKM120 treatment. Representative data from analyses of cell cycle arrest in G2
(d), tubulin polymerization (e), and cell viability (f) after BEZ235 treatment. Data are expressed as mean ± SD and were obtained from three
independent experiments performed in triplicate (Nocod = nocodazole; Paclitax = paclitaxel) ∗𝑝 < 0.01 compared with control.
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3.5. Apoptosis. We next examined the functional effects of
BKM120 and BEZ235 on apoptosis in lymphoma cell lines.
Cells were treated with the IC
50
of BKM120 and BEZ235 for
24 h and 48 h. Apoptotic cells were quantified using annexin
IV/PI staining. Both drugs induced significantly increased
apoptosis even at only 24 hours (𝑝 < 0.01) (Figure 7).
After flow cytometric analysis, we further attempted
to define the mechanisms by which BKM120 and BEZ235
induced apoptosis. We demonstrated that 24 hours of treat-
ment with either compound at IC
50
induced apoptosis via
both intrinsic and extrinsic apoptotic pathways, as demon-
strated by caspase-3, caspase-8, caspase-9, and PARP cleavage
(Figure 8). To confirm that apoptosis wasmediated by activa-
tion of these caspases, we cultured the three cell lines in the
presence of the broad caspase inhibitor ZVAD-fmk. Notably,
NVP-BEZ235 induces cleavage of PARP+ zvad-fmk (data not
shown).
To further analyze the mechanism of apoptosis induced
by BKM120 and BEZ235 inhibition, we measured the expres-
sions of pro- and antiapoptoticmembers of the BCL-2 family,
both before and after treatment with these two compounds.
In all tested lymphoma lines, drug treatment led to increases
of the proapoptotic proteins (Bim, Bad, and PUMA) and
downregulation of the antiapoptotic proteins (BCL-XL and
MCL-1) (Figure 9). BCL-2 expression resulted minimally
affected by BKM120 and BEZ235 treatment.
3.6. Autophagy in LymphomaCells. Aside from its role in reg-
ulating cell growth and proliferation, the PI3K/AKT/mTOR
pathway also participates in autophagy signaling. Therefore,
we investigated whether BKM120, BEZ235, and everolimus
induced autophagy. Everolimus is an mTOR inhibitor and
therefore an autophagy activator [34, 35]. To do this, we
treated all cell lines for 24 hwith the IC
50
of BKM120, BEZ235,
and everolimus, both alone and in combination with the
autophagy inhibitor chloroquine (CQ) and the inhibitor of
autophagosome-lysosome fusion nocodazole [36]. We used
the p62 ELISA kit to evaluate the amounts of p62 protein
(which accumulates when autophagy is inhibited) in cell
lysates, thus allowing quantitative comparison of howHUT78
cells were impacted by the various treatments (Figure 10(a)).
BKM120, BEZ235, and everolimus induced autophagy com-
parable to that which occurs under nutrient deprivation
conditions. In the same samples used to study autophagy, we
also evaluated cellular apoptosis (Figure 10(b)). BKM120 and
BEZ235 alone increased annexin-positive cells, suggesting
that the two drugs induced both apoptosis and autophagy.
CQ and nocodazole alone inhibited autophagy and did
not induce apoptosis, but their cooperative interaction with
BKM120 and BEZ235 triggered apoptosis, as confirmed by
annexin IV/PI staining. Everolimus induced autophagy but
did not induce substantial apoptosis. Comparable results
were obtained with GRANTA519 and WSU-NHL (data not
shown).
As a marker of autophagy, we also monitored lipidation
of LC3II by performing western blotting in all cell lines
following treatment with BKM120, BEZ235, and everolimus
alone and in combination with CQ (data not shown). We
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Figure 7: Cell lines were treated for 24 and 48 h with BKM120 and
BEZ235 at IC
50
. Apoptotic cells were quantified using annexin IV/PI
staining. Each compound dose- and time-dependently induced
increased apoptosis, evidenced by annexin IV positive cells. Results
represent the mean ± SD obtained from three independent experi-
ments. ∗𝑝 < 0.01 compared with control.
also quantitatively determined p62 expression and apop-
tosis (based on caspase-3 expression) in patients’ cells. In
PBMCs from patients and donors, we evaluated the effects
of BKM120, BEZ235, and everolimus both alone and in
combination with CQ (Figures 11(a) and 11(b)). As observed
in the cell lines, BKM120 and BEZ235 induced autophagy and
apoptosis in the patient and donor cells. Everolimus caused
autophagy but did not induce substantial apoptosis. CQ
inhibited autophagy and did not induce substantial apoptosis.
3.7. ROS Expression. Autophagy and apoptosis have been
shown to be regulated by numerous aspects of glucose
metabolism and can also be activated by mitochondrial
dysfunction and oxidative stress [37]. Here we monitored
the generation of reactive oxygen species in cells during
treatment with BKM120 and BEZ235 alone and in com-
bination with CQ. Our results showed that BKM120 and
BEZ235 alone each induced a higher percentage of cells with
ROS generation. This induction was enhanced when these
drugs were combined with CQ. Coadministration of the
antioxidant N-acetyl cysteine (NAC) blocked the increased
ROS generation (Figure 12).
3.8. Combination Study. To determine if this combination
was additive or synergistic, the interaction between BKM120
and BEZ235 in combination with CQ was investigated apply-
ing isobologram analysis based on the Chou-Talalay method.
This analysis was performed using STACorp 8.2 software.We
found that the interaction between BKM120 and CQ showed
moderate synergism (0.5 < CI > 1), while the combination of
BEZ235 and CQ was highly synergistic (CI index < 0.5).
4. Discussion
PI3K inhibitors that are currently under development are
grouped based on their specificity—including pure PI3K
inhibitors, compounds that block both PI3K andmTOR (dual
inhibitors), pure catalytic mTOR inhibitors, and inhibitors
that block Akt. However, it remains unclear which of these
inhibitor types is more clinically effective. Numerous PI3K-
targeted compounds, many of which are dual PI3K and
mTOR inhibitors, are currently being tested in clinical trials
[38, 39].
Here, we evaluated and compared the effects of the pan-
PI3K inhibitor BKM120 and the dual PI3K/mTOR inhibitor
BEZ235 on mantle, follicular, and T-cell lymphomas. Both
drugs effectively induced cytotoxicity in lymphoma cell
lines and patients’ cells. BKM120 and BEZ235 each blocked
the PI3K/Akt/mTOR pathway and the downstream targets
p90RSK and pEBP1, resulting in growth arrest. Our findings
highlight an interesting difference in the actions of the two
drugs with regard to blocking the cell cycle. Treatment with
BKM120 led to a moderate amount of cell cycle arrest in
the G2-M phase in the tested cell lines. In contrast, BEZ235
treatment resulted in substantial dose-dependent accumula-
tion in the G0-G1 phase of the cell cycle. These results were
in agreement with the measured expression levels of cyclins
A, D, and E and the cycle regulators p21 and p27. The two
inhibitors’ different roles in regulating the cell cycle could be
related to their actions onAuroraAkinase expression.Aurora
A kinase belongs to a family of mitotic serine/threonine
kinases that are implicated in important processes during
mitosis andmeiosis [40, 41]. Treatment of our lymphoma cells
with BEZ235 led to a decrease in Aurora A expression, while
BKM120 did not alterAuroraAkinase expression, supporting
a possible key role of this kinase in cell cycle control.
Since BKM120 and BEZ235 showed different roles in
regulating cell cycle blockade, we hypothesized that the two
inhibitors could interfere with microtubule dynamics of the
normal polymerization/depolymerization cycle, resulting in
cell cycle arrest. Microtubule stabilizers (such as paclitaxel
and derivate) and destabilizers (such as nocodazole) activate
the spindle assembly checkpoint, leading to cell arrest in
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mitosis and subsequent cell killing [42]. Our analysis of tubu-
lin expression in lymphoma cell lines revealed that BKM120
acted as a microtubule stabilizer, with an effect similar to
paclitaxel. In contrast, BEZ235 exhibited an action similar
to that of the microtubule destabilizer nocodazole. Further
structural studies are needed to elucidate how BKM120 and
BEZ235 bind to tubulin.
The PI3k/AKT/mTOR pathway plays important roles in
apoptosis and autophagy. When assessing whether BEZ235-
and BKM120-induced cell deathwasmediated through apop-
tosis, we noticed the cleavage of caspases 3, 8, and 9, suggest-
ing activation of both the intrinsic and extrinsic pathways.
Indeed, we observed that apoptotic events were sustained by
upregulation of proapoptotic factors (e.g., BIM, BAD, and
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Figure 11: We quantitatively determined p62 expression (a) and apoptosis (based on caspase-3 expression) (b) in PBMCs from patients and
donors.We evaluated the effects of BKM120 and BEZ235 on PBMCs from three patients withmantle cell lymphoma (MCL), four patients with
follicular cell lymphoma (FCL), two patients with T-cell lymphoma (TCL), and four healthy donors (HD). Results represent the mean ± SD.
PUMA) andwe detected downregulation of the antiapoptotic
factors MCL-1 and BCL-XL. Our results highlight a very
interesting relationship between apoptosis and autophagy.
BKM120 and BEZ235 treatments induced autophagy while
triggering apoptosis. Autophagic machinery-targeted agents
are emerging as promising tools for lymphoma treatment,
and autophagy induction has emerged as a new potential
therapeutic avenue to circumvent cancer cells’ resistance
to cell death [43–45]. However, not all inhibitors of PI3K-
Akt-mTOR signaling synergize with autophagy inhibitors.
The allosteric mTORC1 inhibitor rapamycin does not induce
apoptosis in conjunction with autophagy blockade, due to
feedback-activation of Akt [46].
To better understand the effectiveness of drugs on
autophagocytosis, we treated all lymphoma cell lines with
BKM120, BEZ235, and the rapamycin derivate everolimus,
both alone and in combination with the autophagy inhibitor
chloroquine. Chloroquine is widely used as an effective and
safe antimalarial and antirheumatoid agent. Accumulating
lines of evidence suggest that CQ can effectively sensitize cells
to the effects of conventional cancer therapies (e.g., ionizing
radiation and chemotherapeutic agents) in a cancer-specific
manner, enhancing the treatment efficacy [47]. Our results
showed that both BKM120 and BEZ235 in combination
with CQ cooperated to trigger apoptosis in lymphoma cells.
The potency of these cotreatments was underscored by
the calculated combination index, demonstrating that both
compounds cooperated synergistically.
Accumulating evidence suggests that cancer cells are
under increased oxidative stress and therefore more vul-
nerable to damage by ROS insults induced by exogenous
agents [48]. Reactive oxygen species (ROS) are generated as
by-products of normal physiological processes. The rate of
mitochondrial ROS production can vary depending on cell
physiopathological conditions. However, in any case, only
some ROS produced within mitochondria are released in
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the cytosol [37]. A moderate ROS increase can promote
cell proliferation and differentiation, whereas excessive ROS
can interfere with cellular signaling pathways by causing
oxidative damage to lipids, proteins, and DNA [49]. Our
results showed that both BKM120 and BEZ235 alone induced
a higher percentage of lymphoma cells with ROS generation,
and this increase was enhanced when these drugs were
combined with CQ.We also studied phagocytosis in patients’
cells and the results were comparable to those obtained in the
cell lines. Finally, we did not observe differences between the
different lymphoma types. In conclusion, our results suggest
that BKM120 and BEZ235 can effectively inhibit lymphoma
cell proliferation by causing cell cycle arrest and can lead to
cell death by inducing apoptosis and autophagy mediated by
ROS accumulation.
5. Conclusions
Despite great advances in lymphoma therapy following the
introduction of monoclonal antibodies, many patients still
die from disease progression. Therefore, novel treatment
approaches are needed. BKM120 and BEZ235 alone and
in combination show high effectiveness against lymphoma
cells in vitro. If future studies confirm their effectiveness in
animal models, these drugs may be promising candidates for
development as new drugs.
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